More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerative colitis. The new ...

Last month, the US Food and Drug Administration approved Takeda’s Entyvio subcutaneous administration as a maintenance therapy to treat adults with moderately to severely active Crohn’s disease.

Takeda’s Entyvio remains prominent due to its favourable efficacy and safety profile. Biosimilars of infliximab, adalimumab, and ustekinumab are endorsed as interchangeable, and subcutaneous ...

The Entyvio market has experienced significant ... including approvals for subcutaneous formulations, growing adoption of maintenance therapy, favorable clinical guidelines, reduced systemic ...

Entyvio (vedolizumab) has potential interactions with other medications and certain vaccines. These interactions could affect how well the drug works or cause harmful effects. Entyvio is used in ...